#ampion

https://business.techbooky.com/wipro-to-acquire-cybersecurity-firm-ampion-for-117-million/

Wipro To Acquire Cybersecurity Firm Ampion For $117 million

Indian multinational corporation, Wipro, which majors in providing information technology, consulting and business process services, on Thursday, signed an agreement to acquire Ampion, an Australia-based provider of cybersecurity, DevOps and quality engineering services, for a cash consideration of $117 million.

In a regulatory filing, Wipro mentioned that the acquisition of Ampion is an important step for Wipro in the direction of development, and that it will strengthen the commitment towards clients and stakeholders in Australia and New Zealand (ANZ). The acquisition, which is subject to customary closing conditions and regulatory approvals, is expected to close in the quarter ending June 30, 2021.

Earlier in March, Wipro signed an agreement to acquire Capco, a global management and technology consultancy headquartered in London, for a cash consideration of $1.45 billion, its largest acquisition ever.

The fusion of IT services providers ‘Revolution IT’ and ‘Shelde’ gave birth to Ampion. Revolution IT was an IT services company founded in 2004 in Australia, and Shelde was a digital IT security company founded in 2010 in Australia. Ampion, the outcome of the merged companies, emerged as a cybersecurity, DevOps and quality engineering services provider company. Ampion is headquartered in Melbourne, with offices in Sydney, Brisbane, and a zone 3 facility in Canberra.

Wipro’s APMEA CEO, N.S. Bala, expressed his excitement on the arrival of Ampion to Wipro. He said, “I am excited to welcome Ampion to the Wipro family. Ampion has a successful track record and enjoys immense credibility with leading enterprises in the region, a collaborative work culture, and significant local subject matter expertise. We see Ampion as a complementary force that will help us expand our footprint and accelerate our journey in the Asia Pacific region.”

Ampion’s CEO, Jamie Duffield, showed similar sentiment. He said, “We believe that Ampion’s experience, talent, capabilities and proven client credentials in ANZ, coupled with Wipro’s global scale, leadership in technology, and a deep understanding of domain and delivery, will make us a truly formidable team. We are pleased to become a part of Wipro and look forward to an exciting journey together.”

Wipro buying Australian firm Ampion Rs 858 crore latest news

Image Source : WIPRO Wipro buying Australian firm Ampion for Rs 858 crore Global software major Wipro on Thursday announced buying Australia-based Ampion for $117 million (Rs 858 crore), as it provides cyber security, Dev Ops (software development and IT operations) and engineering services. “The transaction is expected to be completed during the quarter ending June 30, 2021, subject to…

Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) just reported topline from its PIVOT trial and is down more than 60% on the announcement. From this decline alone, it’s clear that the company didn’t report anything great, but despite missing the primary endpoint in the trial, management is shooting for an approval on the data. What are the chances of the FDA giving its candidate the green light, and by proxy, what are the chances an allocation at the current discounted price would turn out to be a rewarding exposure? Let’s try and answer these two questions.

The drug the company is trying to get approved is called Ampion, and it’s targeting the pain associated with osteoarthritis. Much of the pain that osteoarthritis patients suffer from derives from inflammation caused by the condition. Essentially, the joint tissue becomes inflamed, and this leads to a thinning of what’s called articular cartilage – the cartilage that surrounds the end of bones at the joint. This thinning means there is less protection when the joints function, and the bone endings can grind against each other. By targeting the inflammation, a drug can hypothetically halt the thinning of the articular cartilage, while also reducing day to day pain.

Ampion is essentially a brand name for a compound called aspartyl-alanyl diketopiperazine, or DA-DKP. DA-DKP is a molecule that is found organically in human serum albumin, and it has anti-inflammatory qualities. By suppressing the production of certain cytokines (the ones responsible for inflammation) DA-DKP can regulate inflammation, and in turn, serve as the core driver behind the pain management element of an osteoarthritis drug.

Or so Ampio had hoped. Now, it’s not looking so great.

The data that hit press this week came from the above mentioned PIVOT trial. It was a 480 patient phase III, designed to test the safety and efficacy of Ampion across 20 or so sites in the US. The trial measured a baseline using what’s called the Western Ontario and McMaster Universities Arthritis Index (WOMAC), and used this baseline to measure improvement after intra articular injection of Ampion across a twelve-week period. Primary endpoint was simple – an improvement in WOMAC from baseline to week twelve.

This is where things get a bit complicated.

Osteoarthritis is split into 4 grades, called KL grades, varying in severity from low (1) to high (4). Ampio used grades 2-4 for the trial. In all three grades, patients that received the active injection recorded an improvement in WOMAC from baseline, with grade 2 seeing a 52% reduction, grade 3 seeing a 36% reduction and grade 4 a 33% reduction. This is significant, but when compared to placebo, not enough to register as meeting the primary endpoint of the trial.

The grade 4 reduction is the most significant here, despite it being the lowest level of reduction overall. Why? Because normally these patients don’t qualify for these types of trials due to the advanced nature of their condition. That Ampion has shown articular injection of Ampio can reduce WOMAC measured pain by one third after 12 weeks is significant, and it’s this fact that is likely driving management’s decision to carry forward Ampio with an NDA. In fact, chances are, the target indication the company goes for will be this specific subset of OA patients – the grade 4KL patients – as they currently have very limited treatment options outside chronic pain medication. For what it’s worth, the drug was shown to be safe, with little to no AEs and nothing drug-related that warranted discontinuation across the more than 400 tested patients.

So what does all this mean? Can we answer the two posed questions? The first, the chances look OK. The FDA will be fully aware of the limited options grade 4 KL patients have available to them right now, and it wouldn’t be the first time the agency gives a drug the green light despite low efficacy. In short, what’s it got to lose by doing so? To answer the second question, again, pretty good. Of course, if Ampio goes for the trimmed down target population, but analysis suggest late stage OA still occurs in around 10% of healthy weight US adults over 60 and up to 35% in obese US adults over 60, so there’s still plenty of patients to go at.

The company is set to discuss the findings on a conference call early next week, so we might get a bit more info then. Beyond that, a discussion with the FDA, and the resulting actions from that discussion, look to be the major near term milestones.

SAP Sponsors Africa Code Week 2016 to Tackle Continent’s Digital Skills Gap

According to the release from WALLDORF, Germany today, SAP will train more than 150,000 youth in 30 African countries this year to foster digital literacy and equip the continent’s rising generation with job-relevant digital skills. SAP’s Africa Code Week 2016 will run from October 15 – 23, 2016, with thousands of free coding workshops and online training offered to children and youth aged 8 to…

Les activités de cette journée dominicale du 6 décembre fut consacrée et dédiée aux femmes…

Plusieurs tables rondes étaient au programme.La première dont Mr François Adao, secrétaire général, L’Afrique des Idées ( France) fut le modérateur, est intitulée “L’intégration des femmes dans le développement économique du continent“; elle fut ouverte par Mme Marilyn YAV, Présidente, L’Etoile d’Afrique (République du Congo) entourée de Mme Bourgelie AMPION, Secrétaire générale, Fondation AfricaFrance (Congo), Mme Annie BOMBOKO, Maire, Mbandaka (RDC), Mme Juliana LUMUMBA, Ancienne Secrétaire générale, UACCAIP (RDC) et Mme Cyriaque OKOUMOU, Head of Corporate Affairs, Fondation MTN Congo (République du Congo).

“Femmes et enjeux sanitaires” et “L’Afrique au féminin” en partenariat avec Canal+ étaient les autres tables rondes organisées par les femmes  dans le cadre de la Cop 21, Land of African Business, Africa Off Event à L’Hôtel de l’Indusrie à Paris.

Une autre table ronde dénommée “ Le sport, nouveau relais de croissance pour l’ Afrique” a attiré l’attention du public avec la présence de Mr Jimmy Adjovi-Boco, Directeur Général, Diambars, ancien footballeur professionnel (Bénin), Mr Ladji Doucouré, Athlète spécialiste du 110 m haies (France), Mr Hervé Renard, ancien footballeur et entaîneur qui a gagné deux CAN, la Coupe d’Afrique des Nations avec la Zambie en 2012 et la Côte d’Ivoire en 2015 (France).

Une journée  des femmes calme et conviviale malgré les revendications axées sur “…l’Egalité des genres” sans oublier  les enjeux du dérèglement climatique .

Reportage-vidéo et toutes les photos du LAB-2015, Land of African Business sont à suivre sur http://www.belafrikamedia.be et sur http://www.bam-tv.com, votre chaîne qui diffuse 24h/24.

Microsoft 4Afrika partners with AMPION to support African Entrepreurs

  Microsoft 4Afrika has partnered with AMPION to provide Over 200 entrepreneurs all over Africa with  resources, networking opportunities and mentorship needed to start their own businesses. Financial, technical, and mentorship support for this year Venture Buses.

Five buses of 40 entrepreneurs will travel across 16 countries in Africa, entrepreneurs will receive on board mentorship and visit…